Who Smokes? A Profile of Smokers in the US

Publication
Article
Oncology NEWS InternationalOncology NEWS International Vol 8 No 4
Volume 8
Issue 4

ATLANTA-In 1995, an estimated 47 million adults in the United States were current smokers. A “Profile of Smokers” from the American Cancer Society’s Cancer Facts & Figures-1999 shows that, in that year, smoking prevalence was higher for men (27%) than women (22.6%) and highest among American Indians/Alaskan natives (36.2%), compared with other racial and ethnic groups.

ATLANTA—In 1995, an estimated 47 million adults in the United States were current smokers. A “Profile of Smokers” from the American Cancer Society’s Cancer Facts & Figures—1999 shows that, in that year, smoking prevalence was higher for men (27%) than women (22.6%) and highest among American Indians/Alaskan natives (36.2%), compared with other racial and ethnic groups.

Smoking prevalence was highest among men who had dropped out of school (41.9%). Among adult smokers, more than 80% started smoking by age 18, and more than half were already smoking regularly by that age.

In 1997, 36.4% of high school students were current cigarette smokers, ie, smoked at least one cigarette in the past 30 days.

Recent Videos
3 experts in this video
3 experts in this video
3 experts in this video
3 experts in this video
Other ongoing urothelial cancer trials are assessing enfortumab vedotin–based combinations in the neoadjuvant setting.
Given resource scarcity, developing practice strategies for resource-constrained settings would require aid from commercial and government stakeholders.
Approximately 95% of those with a complete response to enfortumab vedotin plus pembrolizumab were alive after 2 years in the phase 3 EV-302 trial.
According to Megan Mullins, PhD, MPH, challenging cultural norms surrounding death and dying may reduce the receipt of low-value end-of-life cancer care.
Thomas Powles, MBBS, MRCP, MD, highlighted fatigue, nausea, and peripheral neuropathy as toxicities observed with enfortumab vedotin plus pembrolizumab.
Related Content